Atea Pharmaceuticals (Nasdaq:AVIR) - Aandelenkoers, Nieuws & Analyse

AVIR Overzicht aandelen

Atea Pharmaceuticals, Inc., een biofarmaceutisch bedrijf in een klinische fase, ontdekt, ontwikkelt en verkoopt antivirale geneesmiddelen voor patiënten met virale infecties.

Over het bedrijf

AVIR fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 119.2% per jaar groeien

Analisten zijn het erover eens dat de aandelenkoers met 112.4% zal stijgen

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

De winst zal naar verwachting de komende drie jaar met gemiddeld 4.8% per jaar dalen.

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Atea Pharmaceuticals, Inc. Concurrenten

Atai Life Sciences

NasdaqGM:ATAI

US$181.2m

Landos Biopharma

NasdaqCM:LABP

US$71.7m

Terns Pharmaceuticals

NasdaqGS:TERN

US$586.0m

Milestone Pharmaceuticals

NasdaqGS:MIST

US$95.3m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Atea Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$3.35
52 Week Hoogtepunt	US$4.60
52 Week Laag	US$2.77
Bèta	0.17
11 maand verandering	-3.18%
3 maanden verandering	1.82%
1 Jaar Verandering	3.40%
33 jaar verandering	-68.84%
5 jaar verandering	n/a
Verandering sinds IPO	-88.96%

Recent nieuws en updates

Recent updates

Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically

Jan 05

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates

Nov 25

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Oct 24

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Oct 24

Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir

Oct 20

U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs

Jun 17

Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

May 15

Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

May 13

Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%

Apr 08

Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business

Mar 06

Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares

Jan 30

Rendement voor aandeelhouders

	AVIR	US Pharmaceuticals	US Markt
7D	-2.0%	-5.0%	-1.9%
1Y	3.4%	14.1%	30.4%

Rendement versus industrie: AVIR presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 14.1 % opleverde.

Rendement versus markt: AVIR presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.4 % opleverde.

Prijsvolatiliteit

Is AVIR's price volatile compared to industry and market?
AVIR volatility
AVIR Average Weekly Movement	6.7%
Pharmaceuticals Industry Average Movement	9.4%
Market Average Movement	6.0%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: AVIR heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van AVIR is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2012	75	Jean-Pierre Sommadossi	ateapharma.com

Atea Pharmaceuticals, Inc., een biofarmaceutisch bedrijf in een klinische fase, ontdekt, ontwikkelt en commercialiseert antivirale geneesmiddelen voor patiënten met virale infecties. De belangrijkste productkandidaat is AT-527, een orale antivirale kandidaat die zich in Fase 3 van de klinische studie SUNRISE-3 bevindt voor de behandeling van patiënten met COVID-19. Het bedrijf ontwikkelt ook bemnifosbubu-3, een antivirale behandeling voor patiënten met een virusinfectie.

Atea Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Atea Pharmaceuticals zich tot de beurswaarde?
AVIR fundamentele statistieken
Marktkapitalisatie	US$277.75m
Inkomsten(TTM)	-US$176.00m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-1.6x

Koers/Winstverhouding

Is AVIR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AVIR resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$75.48m
Brutowinst	-US$75.48m
Overige uitgaven	US$100.52m
Inkomsten	-US$176.00m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 07, 2024

Winst per aandeel (EPS)	-2.08
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde AVIR op de lange termijn?

Bekijk historische prestaties en vergelijking

AVIR Overzicht aandelen

Beloningen

Risicoanalyse

Atea Pharmaceuticals, Inc. Concurrenten

NasdaqGM:ATAI

US$181.2m

NasdaqCM:LABP

US$71.7m

NasdaqGS:TERN

US$586.0m

NasdaqGS:MIST

US$95.3m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Founder notifies of intention to sell stock

Atea Pharmaceuticals Provides Update on Global Phase 3 Rise-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

Independent Director recently sold US$61k worth of stock

Price target increased by 18% to US$5.50

Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Recent updates

Founder notifies of intention to sell stock

Atea Pharmaceuticals Provides Update on Global Phase 3 Rise-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

Independent Director recently sold US$61k worth of stock

Price target increased by 18% to US$5.50

Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Atea Pharmaceuticals, Inc., Annual General Meeting, Jun 21, 2024

Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Founder notifies of intention to sell stock

Atea Pharmaceuticals, Inc. Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment for Phase 3 SUNRISE-3 Trial for COVID-19

Price target decreased by 15% to US$5.33

Atea Pharmaceuticals, Inc. to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD the Liver Meeting 2023

Atea Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Insufficient new directors

Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped from Russell 2000 Defensive Index

Atea Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination

Concentra Biosciences, LLC cancelled the acquisition of 96.37% stake in Atea Pharmaceuticals, Inc. (NasdaqGS:AVIR).

Concentra Biosciences, LLC submitted a non-binding proposal to acquire 96.37% stake in Atea Pharmaceuticals, Inc. (NasdaqGS:AVIR) for approximately $480 million.

Investor sentiment deteriorates as stock falls 16%

Price target decreased to US$9.00

Atea Pharmaceuticals, Inc. Provides an Update on the Clinical Development Programs for 2023

Atea Pharmaceuticals, Inc. Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19

Lead Independent Director notifies of intention to sell stock

Lead Independent Director recently sold US$215k worth of stock

Third quarter 2022 earnings released: US$0.097 loss per share (vs US$0.34 loss in 3Q 2021)

Atea Pharmaceuticals, Inc. Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue

Atea wins FDA Fast Track status for dengue treatment

Investor sentiment deteriorated over the past week

Atea Pharmaceuticals, Inc. to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19

Consensus forecasts updated

First half 2022 earnings released

Atea Pharmaceuticals Q2 2022 Earnings Preview

Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped from Russell 2000 Growth Index

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story

Atea Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2022

Price target decreased to US$10.50

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$11.67

Atea Pharmaceuticals, Inc. Announces Executive Changes

Investor sentiment deteriorated over the past week

Price target decreased to US$15.50

Consensus EPS estimates increase by 131%

Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically

Independent Director recently bought US$103k worth of stock

Consensus forecasts updated

Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in Covid-19

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates

Investor sentiment deteriorated over the past week

Price target decreased to US$16.25

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses

Consensus EPS estimates increase to US$0.62